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L-Selectin - a signalling receptor for lipopolysaccharide 
Rajneesh Malhotra and Michael I Bird 
The activation of leukocytes by bacterial cell-wall are chemically similar and contain Z-keto-3-deoxyoctu- 
lipopolysaccharide contributes to the pathogenesis losonic acid (KDO). The lipophilic lipid A domain, is 
of septic shock. We propose that in neutrophils, and thought to anchor the LPS onto the bacterial outer cell 
possibly other leukocytes, L-selectin can act as a wall. Lysis of the bacterial wall is therefore required for 
low-affinity lipopolysaccharide receptor. Inhibitors of the exposure of lipid A to other binding proteins. Lipid A 
L-selectin may therefore be of therapeutic value in is the principal structure responsible for LPS-induced 
treating this life-threatening condition. sepsis or septic shock. 
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Several LPS-binding proteins have been characterised (for 
review see [3]). The only molecule to date that has been 
implicated directly in LPS binding and LPS-induced acti- 
vation of host cells is the cell-surface CD14 molecule. 
CD14 is a glycerophosphatidyl inositol (GPI)-anchored 
plasma membrane glycoprotein with a molecular weight of 
53 kDa. It is present on monocytes, macrophages and, to a 
lesser extent, on neutrophils [4,5]. High-affinity binding 
of LPS to CD14 requires the presentation of LPS as a 
complex with serum LPS-binding protein (LBP). The 
subsequent signal transduction mechanisms leading to cell 
activation are not well understood. Because CD14 is a 
GPI-anchored cell-surface molecule, it is not itself 
thought to mediate signal transduction [5]. Patients suffer- 
ing from paroxysomal nocturnal hemoglobinuremia are 
unable to form GPI anchors and therefore lack cell-surface 
CD14 and yet monocytes from these patients can be acti- 
vated to secrete cytokines by LPS (with or without LBP) 
[6,7]. In addition, it has been shown that the LPS antago- 
nists, lipid IVA and Rhodobacter sphaeroides lipid A (RSLA), 
inhibit LPS-induced cellular signalling by interacting with 
cell-surface protein(s) distinct from CD14 [8]. Further- 
more, macrophages isolated from mice lacking the CD14 
gene (CD14 knockout), have been shown to respond to 
LPS, but only at higher concentrations of LPS [9,10]. In 
the CD14 gene-knockout animals it was shown that the 
macrophage interaction with low concentrations of LPS 
(< 10 rig/ml) was CD14 dependent. At higher concentra- 
tions of LPS, no difference in TNF-cx secretion was 
observed between macrophages from CD14 knockout and 
wild-type mice. These observations point to the existence 
of CD14-independent signalling mechanism(s) for LPS- 
induced cell activation [lo]. Results obtained from the 
CD14-knockout animals are consistent with anti-CD14 
antibodies studies in mice. It is known that, in viva, high 
concentrations of LPS (> 100 @ml) can stimulate mono- 
cytes and neutrophils to produce cytokines without the 
involvement of CD14/LBI? Depletion of serum LBP by 
anti-LBP antibodies had little effect on the survival rate of 
mice injected with high doses of LPS [ll,lZ]. 
Lipopolysaccharide (LPS), an outer membrane compo- 
nent of Gram negative bacteria, is a potent activator of 
leukocytes and endothelial cells. LPS stimulates cells to 
express a series of genes coding for immunoregulatory, 
inflammatory and cytotoxic molecules, such as tissue 
factor, tumor necrosis factor a (TNF-a), interleukin (IL)-1 
and IL-6. The excessive secretion of these mediators 
results in pathophysiological effects in humans, causing 
symptoms of sepsis or septic shock. Characteristic symp- 
toms of sepsis are fever, hypothermia and an increased 
white blood cell count; septic shock is a form of acute cir- 
culatory failure. Septic shock is a life-threatening condi- 
tion, considered to be the commonest cause of death 
within intensive care units. An estimated 500,000 people 
are affected annually by this syndrome in the USA alone. 
Mortality is typically 40-60% within 28 days of diagnosis, 
despite antibiotic therapy and state-of-the-art intensive 
care medicine. Septic shock patients die of cardiovascular 
prolapse and multiple organ failure exacerbated by a 
locally inadequate blood supply (ischaemia) and an infil- 
tration of leukocytes in the tissue [l]. It is known that in 
&JO a concentration of < l&ml of LPS is sufficient to 
induce the symptoms of sepsis, although higher concen- 
trations of LPS (>lOO @ml) are required to produce 
symptoms of septic shock [l]. How does LPS produce 
such dramatic effects? 
LPS characteristically consists of a polysaccharide region 
with a covalently bound lipid A component (Figure la). 
The polysaccharide region consists of an O-specific chain, 
an outer core of sugar moieties and a conserved inner-core 
oligosaccharide [Z]. The O-specific chain is characteristic 
for a given LPS and varies between different species and 
serotypes of bacteria. The inner core of a variety of LPSs 
CD14 also exists in a soluble form in plasma at a concentra- 
tion of 2-6 pLg/ml [13]. Soluble CD14 can bind LPS 
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The structure of carbohydrate and glycolipid 
ligands for L-selectin. (a) Lipopolysaccharide; 
(b) sulphated sialyl Lewis X; and (c) sulphatide. 
The likely binding site for L-selectin on each 
ligand is shown in red. 
without a requirement for LBP [13,14]. The soluble CD14/ 
LPS complex has been shown to bind to CDlCnegative 
cells, for example endothelial cells, and to induce the 
secretion of cytokines from these cells [13,14]. Thus, 
CD14 is clearly not the only component required for LPS 
signalling, and the identity of the second component of the 
signalling receptor has, until recently, remained a mystery. 
Selectins 
Selectins are cell-surface integral membrane glycoproteins 
reported to be involved in leukocyte trafficking, thrombosis 
and inflammation. The three known selectins (E-selectin, 
P-selectin and L-selectin) are characterised by an amino- 
terminal carbohydrate recognition domain (CRD) followed 
by an epidermal growth-factor domain, two to nine comple- 
ment control protein domains, a single membrane-spanning 
region and a cytoplasmic carboxy-terminal cytoplasmic 
domain (Figure 2). E-selectin is expressed principally on 
endothelium in response to inflammatory stimuli such as 
IL-l, TNF-a and bacterial lipopolysaccharides. P-selectin 
expression is also induced on endothelium and platelets in 
response to inflammatory responses. E-selectin expression 
is induced at the level of transcription, but P-selectin is 
stored in the a-granules and Weibel-Palade bodies of 
platelets and endothelium. L-selectin is expressed on 
essentially all blood leukocytes (for review, see [ 151). 
The generation of mice lacking individual selectins and in 
O~UO studies with anti-selectin antibodies have provided 
insight into the physiological role of selectin-mediated 
adhesion (for review, see [16]). These data indicate that 
L-selectin and P-selectin mediate the initial capturing of 
leukocytes from the streaming blood, while the synergistic 
action of L-selectin and E-selectin or P-selectin is required 
for optimal and stable leukocyte rolling (the first stage in 
the process by which leukocytes exit blood vessels near a 
site of infection; selectins provide weak adhesion to the 
endothelial cell wall, allowing the leukocyte to roll along it). 
On the basis of either direct binding or inhibition experi- 
ments, it has been shown that selectins share a common 
feature in recognising selectin ligands. The three selec- 
tins bind to fucosylated, sialylated oligosaccharides, such 
as sialyl Lewis X (sLex, NeuAca2-3,GalBl-4(al-3Fuc) 
GlcNAc) in the presence of Ca2+ ions (Figure 1 b). 
Although the binding affinity of selectins for sLeX is in 
the low millimolar range, it has been suggested that 
higher avidity is achieved either through multiple 
binding or through the interaction of selectin (P-selectin 
or L-selectin) with a sulphated side group on the carbo- 
hydrate or protein backbone. P-selectin and L-selectin 
have also been reported to bind to heparan sulphate, 
glycosaminoglycans and sulphated glycolipids. These 
ligands lack sialic acid and fucose and can interact with 
selectins in the presence of EDTA, suggesting that they 
bind at a site distinct from the classical Ca2+-dependent 
carbohydrate recognition domain [15]. 
Malhotra et al. [ 171 recently reported that charged phospho- 
lipids, such as cardiolipin and phosphatidylserine, bound 
to L-selectin in the presence of EDTA. This binding was 
shown to take place with a specific site on the C-type 
lectin domain of L-selectin incorporating the basic 
sequence KKNKE. A similar sequence (KRGK) has also 
been suggested to be a binding site for heparan sulphate 
on B-chemokines, for example MIP-la [18]. It is likely that 
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Figure 2 
A schematic representation of the domain 
structure of the three selectins, and the cells 
that express them. The carbohydrate (CHO) 
ligands for L-selectin are expressed on 
endothelium; most leukocytes express ligands 
for E-selectin and P-selectin. Leukocytes bind 
to endothelium using L-selectin to bind to the 
carbohydrates expressed on endothelium; in 
contrast, neutrophils and monocytes use 
carbohydrate structures to bind to the 
E-selectin or P-selectin expressed on the 
endothelium. 
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the Ca2+-independent binding of L-selectin to charged naive (CD45RA+) T cells with GlyCAM-1 (an L-selectin 
lipids or glycolipids takes place through the phospholipid- ligand, which carries sulphated sLeX; Figure lb) results in 
binding site. Thus, it seemed possible that L-selectin the activation of the T cell, as detected by the expression 
might also bind to other lipid-linked, negatively charged of a neoepitope on BZ-integrins which is associated with a 
structures, such as LPS. high-avidity state. 
L-Selectin as a signaling receptor L-Selectin and septic shock 
Evidence has been accumulating that L-selectin is also a 
signalling receptor. Sulphatides are 3-sulphated galacto- 
cerebrosides (a sulphate group is esterified on position 3 of 
the galactose; Figure lc); they interact with several pro- 
teins, including laminin, thrombospondin, von Willebrand 
factor, properdin, antistasin and gp120 [19] .Recently, it has 
been reported that these compounds bind to L-selectin or 
P-selectin but not to E-selectin [20,21]. Ligation of cell- 
surface L-selectin on neutrophils with sulphatides or cross- 
linking with anti-L-selectin antibodies has been reported 
to induce transmembrane signalling [Z]. Interaction of 
sulphatides or anti-L-selectin antibodies with neutrophils 
triggers an increase in intracellular free calcium, the release 
of oxygen radicals and an enhanced expression of cytokine 
mRNA (such as TNF-cx and IL-8) [2’2,23]. This effect is 
dependent on the sulphation of the galactose ring, as non- 
sulphated galactocerebrosides did not bind to L-selectin 
and were also non-stimulatory. Binding of sulphatides to 
L-selectin or P-selectin is Ca2+ independent and it has 
been suggested that the sulphatides interact with L-selectin 
through a site distinct from the carbohydrate-binding site. 
We suggest that sulphatides interact with the anionic 
binding site on L-selectin in a manner similar to charged 
phospholipids [17]. 
The idea that L-selectin might be involved in the mortality 
associated with septic shock was first suggested by experi- 
ments performed by Tedder et al. [26]. High doses of LPS 
(40 l.tg of LPS per g of body weight) were injected into 
L-selectin-deficient and wild-type mice. In the wild-type 
mice 90% mortality was observed within 24 h, whereas in 
the L-selectin-deficient mice 90% of mice were still alive 
after 24 h. The majority (60%) of L-selectin-deficient mice 
survived the LPS-induced septic shock and appeared 
normal after four days. Tedder et al. suggested that resis- 
tance to LPS-induced mortality in L-selectin-deficient 
mice could be due to impaired recruitment and accumula- 
tion of leukocytes in tissues. But it has recently become 
clear that there may be another explanation for these find- 
ings. We recently reported that L-selectin binds to LPS 
isolated from several bacteria [27]. Both the binding of 
LPS to neutrophils and the LPS-induced activation of 
neutrophils was inhibited by anti-L-selectin antibodies. 
Our results indicate that L-selectin has a dual role: first as 
an adhesion molecule involved in leukocyte rolling, and 
second as a signalling receptor for LPS. 
Further evidence that L-selectin can mediate signalling 
comes from studies of lymphocyte trafficking [24,25]. 
Hwang and coworkers [ZS] reported that the treatment of 
Further evidence for the role of L-selectin in LPS-induced 
signalling was provided by Higashi et al. [19] who reported 
that LPS-induced TNF-a secretion from the human 
monocyte cell line, THP-1, was inhibited by sulphatide in 
a dose-dependent manner. As discussed above, sulphatides 
bind to L-selectin and at higher concentrations (400 yglml) 
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Figure 3 
A proposed model for the role of L-selectin 
and CD1 4 in lipopolysaccharide (LPS)- 
induced cytokine release from leukocytes. 
Bacterial lysis releases LPS, which binds 
either to LPS-binding protein (LBP) or directly 
to L-selectin. The LPSlLBP complex can bind 
to the glycerophosphatidyl inositol (GPI)- 
anchored receptor CD1 4, and this complex in 
turn can bind to an unidentified signalling 
receptor, which may or may not be L-selectin. 
Both L-selectin and the unidentified signalling 
receptor trigger intracellular events that lead 
to Ca*+ influx and eventually to cytokine 
release, hence to sepsis or septic shock. 
can induce L-selectin-mediated transmembrane signalling. 
Due to the hydrophobic lipid sidechain, sulphatides at 
higher concentration tend to form micelles in water. It has 
been suggested that micelles of sulphatides can cross-link 
cell-surface L-selectin and mediate cell activation. But at 
lower concentrations (cl00 @ml), sulphatides exist pri- 
marily in a monomeric form in which they can act as antag- 
onists of L-selectin [19]. Higashi et al. [19] also reported 
that pretreatment of mice with sulphatide inhibited LPS- 
induced acute mortality, hypotension and the increase in 
levels of serum TNF-a. The degree of protection against 
LPS-induced mortality offered by sulphatide pretreatment 
in -ho was very similar to that reported by Tedder et al. 
[26]. Furthermore, rabbits pre-treated with anti-L-selectin 
antibodies were also resistant to LPS-induced septic shock 
[ 191. The data from Higashi etaI. [ 191 support our interpre- 
tation that L-selectin is a receptor for LPS and that inhibi- 
tion of the interaction between L-selectin and LPS could 
be beneficial in treating severe symptoms associated with 
septic shock. 
Further indirect evidence for the involvement of L-selec- 
tin in septic shock was provided by Donnelly et al [B]. 
It is well established that the cross-linking of cell-surface 
L-selectin and the subsequent activation of leukocytes 
causes proteolytic cleavage and shedding of L-selectin [29]. 
Donnelly et al. [28] found a significant correlation between 
plasma levels of soluble L-selectin and the propensity to 
develop adult respiratory distress syndrome (ARDS). 
Patients with ARDS were suffering from multiple trauma, 
pancreatitis and perforated bowel. Their findings indicated 
that patients who subsequently developed ARDS had low 
levels of soluble L-selectin compared with patients who 
did not develop ARDS. It is likely that the patients with 
high levels of soluble L-selectin are resistant to ARDS due 
to inhibitory effects of soluble L-selectin on the interaction 
of LPS with leukocytes [ZS]. In future it will be useful to 
establish whether low levels of soluble L-selectin could be 
used as an indicator for the risk of progressing from sepsis 
to septic shock in patients. 
We therefore propose that L-selectin has a dual role: first as 
an adhesion molecule involved in leukocyte rolling, and 
second as a signalling receptor for LPS. CD14 in the pres- 
ence of LBP is a high-affinity receptor for LPS. At low con- 
centrations of LPS, the binding of LPS to leukocytes is 
mainly through LBP/CD14 and thus the presence of LBP 
and CD14 is necessary for the activation of leukocytes. As 
. 
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CD14 is not considered to be a signalling molecule, it has 
been suggested that CD14-associates with a distinct sig- 
nailing receptor. It is possible that L-selectin could be the 
CD14-associated low-affinity signalling receptor. But at 
higher concentrations, LPS binds directly with L-selectin 
and does not require cooperativity between CD14 and 
L-selectin. In Figure 3, we propose a model for the role of 
L-selectin in LPS-induced cellular responses. These find- 
ings suggest that inhibitors of L-selectin may be of thera- 
peutic value in treating the life-threatening condition 
septic shock. 
In our opinion, future research should be aimed at devel- 
oping specific inhibitors for LPS-L-selectin binding. The 
inhibitor(s) should act as an antagonist and not an agonist 
of L-selectin-mediated signalling. Higashi et al. [19] have 
shown that sulphatides, depending on concentration and 
their tendency to form micelles, can act as an agonist or 
antagonist of L-selectin-mediated signalling. One possible 
approach is to synthesise sulphatides with less tendency to 
form micelles, for example by modifying the lipid acyl 
chains. Another approach would be to search for inhibitors 
of L-selectin through screening or rationale design based 
on the putative anionic binding site [17] for LPS on 
L-selectin. An antagonist of L-selectin-mediated signalling 
will be useful both towards proving our hypothesis and 
,towards a lead for a therapeutically useful drug. 
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